Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays
FEBS Open Bio, Volume 16, Issue 2, Page 314-330, February 2026.We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul +3 more
wiley +1 more source
Efficacy and safety of tenecteplase for acute ischemic stroke within an extended treatment window: a systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials [PDF]
Journal of Neurocritical CareBackground In acute ischemic stroke (AIS), the treatment window for thrombolytics is 4.5 hours from symptom onset. Tenecteplase, a modified tissue plasminogen activator, may be effective over an extended treatment window (4.5–24 hours).
Hesham Kelani +15 more
doaj +1 more source
Initial experience with the left ventricular assist device TransCoreTM [PDF]
, 2010 Cardiogenic shock is a condition associated to high mortality rates. For decades, the treatment consisted of vasoactive drugs and intra-aortic balloon pump.
Alves, Claudia Maria Rodrigues +3 more
core +1 more source
From Innovation to Validation: Strengthening Interventional Radiology Through Data
Journal of Medical Imaging and Radiation Oncology, EarlyView.
Kaiwen Cabbabe +3 more
wiley +1 more source
Frontiers in NeurologyObjectiveTo systematically compare the benefits and risks of all thrombolytic agents (tenecteplase, reteplase, and alteplase) at different doses for thrombolytic therapy in patients with acute ischemic stroke (AIS).BackgroundAlteplase is the cornerstone ...
Li-Chao-Yue Sun +8 more
doaj +1 more source
Successful use of Tenecteplase in a patient with recurrence of prosthetic mitral valve thrombosis
Indian Heart Journal, 2015 Introduction: Tenecteplase can be a more effective and convenient alternative in treatment of prosthetic valve thrombosis (PVT). Case: We hereby present a case of the use of Tenecteplase for recurrence of mitral valve thrombosis in a patient who was ...
Harshal A. Lahoti, Bal Krishna Goyal
doaj +1 more source
Review of Protocols Used in Ultrasound Thrombolysis [PDF]
, 2017 Objectives: This paper focuses on the review of protocols used in thrombolysis studies with ultrasound. Materials and methods: Data from peer-review articles were acquired.
Damianou, C. +2 more
core +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 2, February 2026.Pachymic acid protects blood–brain barrier (BBB) integrity by decreasing the degradation of tight junction proteins caused by tissue plasminogen activator (tPA). Pachymic acid activates the PI3K/Akt pathway via direct binding to PI3K protein, mitigating BBB damage and hemorrhagic transformation induced by tPA after ischemic stroke.
Yongshi Wu +7 more
wiley +1 more source
Bibliometric analysis of the usage of tenecteplase for stroke
International Journal of Emergency MedicineIntroduction In recent years, tenecteplase has been competing with alteplase as a treatment for acute ischemic stroke given its ease of administration, lower dosage, cost-effectiveness, and better safety data.
Garv Bhasin, Latha Ganti
doaj +1 more source
Fixed low-dose ultrasound-assisted catheter-directed thrombolysis for intermediate and high-risk pulmonary embolism [PDF]
, 2017 Aims No standardized local thrombolysis regimen exists for the treatment of pulmonary embolism (PE). We retrospectively investigated efficacy and safety of fixed low-dose ultrasound-assisted catheter-directed thrombolysis (USAT) for intermediate- and ...
Baumann, Frederic +8 more
core